IN8bio reports updated glioblastoma data at SNO 2026, with 20.9-month median survival and 50% two-year survival
INAB•IN8bio reported median overall survival of 20.9 months and two-year survival of 50% among repeat-dose patients receiving gamma-delta T cell therapy. The company also reported median progression-free survival of 13.0 months, compared with 6.6 months for standard of care.
1. Updated glioblastoma data
IN8bio reported updated glioblastoma data at SNO 2026, with median overall survival of 20.9 months and 50% of repeat-dose patients alive at two years, versus 10% for standard of care. Median progression-free survival among repeat-dose patients was 13.0 months, compared with 6.6 months for standard of care. The company reported no CRS, ICANS, major infections or treatment-related serious adverse events.




